Clal Biotechnology (Israel) Buy Hold or Sell Recommendation
| CBI Stock | 46.40 1.60 3.57% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Clal Biotechnology Industries is 'Strong Sell'. Macroaxis provides Clal Biotechnology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CBI positions. The advice algorithm takes into account all of Clal Biotechnology's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Clal Biotechnology's buy or sell advice are summarized below:
Real Value 35.17 | Hype Value 45 | Market Value 46.4 | Naive Value 47.94 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Clal Biotechnology Industries given historical horizon and risk tolerance towards Clal Biotechnology. When Macroaxis issues a 'buy' or 'sell' recommendation for Clal Biotechnology Industries, the advice is generated through an automated system that utilizes algorithms and statistical models.
Clal |
Execute Clal Biotechnology Buy or Sell Advice
The Clal recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Clal Biotechnology Industries. Macroaxis does not own or have any residual interests in Clal Biotechnology Industries or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Clal Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Clal Biotechnology Trading Alerts and Improvement Suggestions
| The company reported the revenue of 76.96 M. Net Loss for the year was (89.58 M) with profit before overhead, payroll, taxes, and interest of 10.72 M. | |
| Clal Biotechnology Industries has accumulated about 94.71 M in cash with (41.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59. | |
| Roughly 65.0% of the company shares are held by company insiders |
Clal Biotechnology Returns Distribution Density
The distribution of Clal Biotechnology's historical returns is an attempt to chart the uncertainty of Clal Biotechnology's future price movements. The chart of the probability distribution of Clal Biotechnology daily returns describes the distribution of returns around its average expected value. We use Clal Biotechnology Industries price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Clal Biotechnology returns is essential to provide solid investment advice for Clal Biotechnology.
| Mean Return | 0.17 | Value At Risk | -4.2 | Potential Upside | 5.09 | Standard Deviation | 2.65 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Clal Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Clal Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Clal Biotechnology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Clal Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Clal stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.09 | |
β | Beta against NYSE Composite | 0.81 | |
σ | Overall volatility | 2.62 | |
Ir | Information ratio | 0.03 |
Clal Biotechnology Volatility Alert
Clal Biotechnology Industries currently demonstrates below-average downside deviation. It has Information Ratio of 0.03 and Jensen Alpha of 0.09. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Clal Biotechnology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Clal Biotechnology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Clal Biotechnology Fundamentals Vs Peers
Comparing Clal Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Clal Biotechnology's direct or indirect competition across all of the common fundamentals between Clal Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Clal Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Clal Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Clal Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Clal Biotechnology to competition |
| Fundamentals | Clal Biotechnology | Peer Average |
| Return On Equity | -0.45 | -0.31 |
| Return On Asset | -0.12 | -0.14 |
| Profit Margin | (1.14) % | (1.27) % |
| Operating Margin | (0.86) % | (5.51) % |
| Current Valuation | 89.12 M | 16.62 B |
| Shares Outstanding | 156.85 M | 571.82 M |
| Shares Owned By Insiders | 64.58 % | 10.09 % |
| Price To Earning | (218.28) X | 28.72 X |
| Price To Book | 0.68 X | 9.51 X |
| Price To Sales | 2.79 X | 11.42 X |
| Revenue | 76.96 M | 9.43 B |
| Gross Profit | 10.72 M | 27.38 B |
| EBITDA | (98.18 M) | 3.9 B |
| Net Income | (89.58 M) | 570.98 M |
| Cash And Equivalents | 94.71 M | 2.7 B |
| Cash Per Share | 0.59 X | 5.01 X |
| Total Debt | 52.28 M | 5.32 B |
| Debt To Equity | 6.30 % | 48.70 % |
| Current Ratio | 3.67 X | 2.16 X |
| Book Value Per Share | 0.84 X | 1.93 K |
| Cash Flow From Operations | (41.33 M) | 971.22 M |
| Earnings Per Share | (0.57) X | 3.12 X |
| Target Price | 30.0 | |
| Number Of Employees | 21 | 18.84 K |
| Beta | 0.9 | -0.15 |
| Market Capitalization | 122.65 M | 19.03 B |
| Total Asset | 444.92 M | 29.47 B |
| Retained Earnings | (823 M) | 9.33 B |
| Working Capital | 193 M | 1.48 B |
| Current Asset | 254 M | 9.34 B |
| Current Liabilities | 61 M | 7.9 B |
| Z Score | -0.2 | 8.72 |
| Annual Yield | 0.18 % |
Clal Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Clal . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Clal Biotechnology Buy or Sell Advice
When is the right time to buy or sell Clal Biotechnology Industries? Buying financial instruments such as Clal Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Clal Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Restaraunts Hotels Motels Thematic Idea Now
Restaraunts Hotels Motels
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Restaraunts Hotels Motels theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaraunts Hotels Motels Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Clal Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Clal Stock analysis
When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |